5 percent of 10th- and 12th-graders say they've used nicotine pouches
More U.S. high-schoolers used nicotine pouches — smokeless nicotine powder products — last year than the year before, according to new research published in JAMA Network Open.
The researchers, who used data from a nationally representative survey of 10,146 youths in 2023 and 2024, said 5.4 percent of 10th- and 12th-graders reported having used nicotine pouches, up from 3 percent the year before. The 10th- and 12th-graders' use of pouches in the 12 months and 30 days before the surveys also increased year to year. Males were also more likely to use pouches than females.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program Lehi, Utah, June 09, 2025 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body's immune system to treat cancer, today announced that it will expand its preclinical program to include liver cancers, specifically rare stem cell-like forms of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Patients with these stem cell-like tumors have a significantly worse survival than patients with more traditional liver tumors. CancerVax's novel platform uses engineered lipid nanoparticles to detect and mark only cancer cells for destruction by the immune system. The nanoparticles use a 2-step detection mechanism to precisely target cancer cells, while leaving healthy cells unharmed. The nanoparticles first target cells with specific surface proteins ('Marker1'), then release proprietary Smart mRNAs that are activated only in the presence of cancer-specific signatures ('Marker2'). Once activated, the mRNA forces cancer cells to express proteins associated with well-immunized diseases like measles, effectively tricking the immune system into killing cancer cells as if they were common diseases. The Company previously announced that it was targeting pancreatic ductal adenocarcinoma (PDAC) in its preclinical program. After extensive research and AI-driven analysis, the Company's scientific team has discovered a very distinct Marker2 signature for a group of rare liver cancers. These tumors have stem cell characteristics, making them more aggressive and less responsive to traditional therapies. By taking advantage of the distinct Marker2 signature, CancerVax believes it can overcome the severe unmet clinical need for these cancer patients and can more quickly validate the universality of its platform. The Company's preclinical cancer indications will now be expanded to three (3) cancer types: PDAC, rare HCC and ICC. Dr. Adam Grant, Principal Scientist of CancerVax said, "When we first identified these subsets of liver cancers with this distinct Marker2 signature, I couldn't believe it. It was amazing to come across a patient population that has a high unmet clinical need and is uniquely suited to validate our technology. Of course, we expect that our platform will work on many different cancer types but the unique genetic signatures in these rare liver cancers make them a no-brainer for us to target. This precision-based discovery is what every computational biologist dreams of and I'm beyond excited to have the opportunity to help provide relief for these patients with severely poor outcomes. Dr. George Katibah, Chief Scientific Officer of CancerVax said, "The results from our AI data analytics are really striking. This particular cancer biology leads to not one but a group of rare liver cancers for which there are limited treatments. Our team has uncovered this novel cancer stem cell biology using advanced computational techniques showing that these tumors' underlying biology can be targeted by the CancerVax approach. These results demonstrate the flexibility of our platform and how we can swap out Marker1 and Marker2 to attack other cancers with a precision medicine approach. The next steps include creating new nanoparticles for these new cancer indications and to perform in vitro and in vivo studies to evaluate efficacy and safety.' The Company's universal cancer treatment platform is architected in such a way that off-the-shelf injections can be created by changing the Marker1 and Marker2 combination to target different cancer types. This approach allows for the Company's immunotherapies to be broadly available when a patient is diagnosed and needs to be treated immediately. These injections are more like 'off-the-shelf' flu shots, rather than complex treatment procedures. About CancerVax CancerVax is a pre-clinical biotech company developing a novel Universal Cancer Treatment platform that will be customizable, as an injection, to treat many types of cancer. Our innovative approach DETECTS, MARKS, and KILLS only cancer cells. By making cancer cells look like well-immunized common diseases such as measles or chickenpox, we intend to use the body's natural immune system to easily kill the cancer cells. We look forward to the day when treating cancer will be as simple as getting a shot -- a better way to fight cancer. To learn more, please visit Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results and financial condition may differ materially from those in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise. Press Contact:CancerVax, (805) 356-1810Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Eric Adams signs executive order adopting Holocaust remembrance group's definition of antisemitism
Mayor Eric Adams signed an executive order Sunday adopting the International Holocaust Remembrance Alliance's definition of antisemitism, as he vowed to ramp up the city campaign to combat Jew hatred. He also introduced legislation urging the City Council to approve the IHRA definition, which would make it official law. The IHRA definition is considered by many Jewish leaders to be the standard in fighting antisemitism. 'Antisemitism is a certain perception of Jews, which may be expressed as hatred toward Jews. Rhetorical and physical manifestations of antisemitism are directed toward Jewish or non-Jewish individuals and/or their property, toward Jewish community institutions and religious facilities,' the IHRA definition states. Adams announced the order during a discussion with Dr. Phil Sunday night at the Tribeca Synagogue. It comes as he faces re-election and plans to run as an independent on an 'End Semitism' ballot line. 'Antisemitism is a vile disease that's been spreading across our nation and our city. What's worse, since Hamas' terror attacks on October 7, 2023, we have seen this hateful rhetoric become normalized on our campuses, in our communities, and online as antisemitic propaganda far too often masquerades as 'activism,'' Adams said. More than half of the hate crimes reported in the city in March victimized Jews, even though they account for just 11 percent of the population, the mayor noted. 'We know this moment demands bold, decisive action to crack down on anti-Jewish hatred,' Adams said. 'Today, we signed a landmark executive order to adopt an internationally recognized definition of antisemitism, but we must go further. I am calling on the City Council to join this commitment to target antisemitism everywhere it exists and immediately pass a bill to codify this definition into law. It's time we all come together to eradicate this hatred from our city, once and for all.' At the state level, former Gov. Andrew Cuomo — who's also running for mayor — issued an order barring state entities from doing business with firms that back the boycott, divestment and sanctions movement against Israel before his resignation. Gov. Kathy Hochul has retained the policy. State Comptroller Tom DiNapoli has his own pro-Israel policy. In 2021, he announced that he pulled $111 million in investments out of the firm that owns Ben & Jerry's because of the ice cream maker's boycott of Israel's occupied territories. DiNapoli is the sole manager of the $274 billion state Common Retirement Fund.
Yahoo
an hour ago
- Yahoo
28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains
Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025 /PRNewswire/ -- 28bio today announced the Nexon™ neurotechnology platform—a major advancement in understanding human brain function. The platform integrates tissue engineering, neural interfacing and AI to engineer human brains at-scale and replicate complex neurological processes. The Nexon™ platform is now being used to improve the prediction of therapeutic efficacy and toxicity in humans, with several of the world's largest pharma companies already integrating Nexon™ into their drug development workflows. The Nexon™ platform also incorporates Organoid Intelligence (OI). The growing field of OI combines human brain organoids with brain-machine interfaces to model memory, learning, and cognition in vitro, offering novel functional cognitive biomarkers with the potential to reshape drug development in neurodegenerative disorders including Alzheimer's disease. Neurological drug development faces some of the highest failure rates in the pharmaceutical industry, due to poor translatability of animal models. Despite promising preclinical study results, many therapies ultimately fail in humans—contributing to a growing neurological health crisis and need for more predictive, human-relevant models. "We engineer human brains capable of elucidating the complexity of neurological processes and produce predictive data needed to change the trajectory of neurological drug development," said Alif Saleh, CEO of 28bio. "Industry and regulators are urgently asking for solutions to develop better neurological drugs faster and cheaper." About 28bio28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today's neurological health crisis by improving the ability to predict which therapies will work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human cognition. For more information, visit View original content to download multimedia: SOURCE 28bio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
